Stifel raised its price target for ARIAD shares to $10 after the FDA said the company can resume marketing of Iclusig in the U.S. Stifel views the FDA's approval positively for the European Medicine Agency's review of Iclusig which started on December 5. The firm expects a quick uptake in U.S. sales, and raised its 2014 revenue estimate to $125M from $120M. It keeps a Buy rating on the stock.
should be over $10-$12 next week
Going to shift $10k more into account for 1500sh more for total 5000shares- ARIA is going double digits in few days
Found the revenue projection numbers for $1.5 billion in projected revenue Iclusig
what gives ??????????
at $6.50 ARIA is a 1Billion market cap-----anyone know the reason this was $20billion ++++??????
Happens everytime- way way oversold
Hope it stays here tomorrow open-will be opening large LONG position-
AGAIN- look at 5 year chart !!!!!!!!!!!!
They are not allowed- I understand that Sanofi has increased its stake and filed to increase it more- but REGN does not want that and they have an agreement with Sanofi that extends somewhere to 2020 I believe that caps Sanofi's stake in REGN-
So anyway- as a REGN holder you dont want a buyout- The potential of the pipeline makes REGN a CELG or BIIB company-----double what they are right now============60 Billion +
Whoever is now out- Strong buying rest of year---
Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) stays on the list at Piper Jaffray for 2014. With treatments for everything from macular degeneration to colorectal cancer, the company continues to exploit an extraordinary pipeline. The company is viewed by many Wall Street firms as a leading candidate to be one the next generation biotech large cap leaders. Piper Jaffray has placed a huge $376 price target on the stock. The consensus is at $339.50. Regeneron closed Monday at $261.88.
That is a very safe play- I dont believe it will yield more than 5% over following months- CELG,REGN,BIIB being combined 24% or so would with 10% will yield about 3% max and with others maybe 5%. I would look very hard at REGN here- $254 or so is 200DMA- I feel this pullback from above $300 is temporary over next few days or weeks. Typically the first week of the new year will see REGN up over $300 going into earnings FEB and most of all revs 2014 from DME indication will triple Eylea sales.
Good luck- but a little to safe for me
The FDA made REGN conduct massive trials (in the USA) with up to 3000 patients (2400 or so in last one before 11/2011 approval). The 2 main companies now are conducting small trials (250 or so) and, and this is a big "and"; they are not being conducted all at the same location with the same criteria and also overseas (i.e.: FDA would not even look at having a trial spread out over 11 locations; experimentally inaccurate. The tiny companies are very interesting though and I have been watching them but they are literally years and years away with massive amounts of money needed to conduct “Gold-Standard "Eylea like trials for FDA consideration.
Another important point is the delivery method issue (problem): The chemistry involved with the other molecules involves a very difficult path for establishing enough saturation behind the macula. These companies are basically buying time to showcase their molecules and they will either run out of funding and go belly-up or show "some" promise and be funded. Either way its years away and boatload of money needed to conduct trials like Eylea's.
One last comment- In 2014 Eylea will be used to treat DME; huge market and Doctors will become extremely familiar with Eylea (up to 10X more market than Eylea already has). Doctors like familiarity and hence by 1-3 years Eylea's revs will be 5 times that of 2013------5 billion looks attainable in a short period of time.